Defence Therapeutics Inc. (DTC) - Total Assets
Based on the latest financial reports, Defence Therapeutics Inc. (DTC) holds total assets worth €1.37 Million EUR (≈ $1.60 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Defence Therapeutics Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Defence Therapeutics Inc. (DTC) market capitalisation for the company's overall valuation and market capitalisation.
Defence Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (June 2024)
Defence Therapeutics Inc.'s total assets of €1.37 Million consist of 44.8% current assets and 55.2% non-current assets. Review Defence Therapeutics Inc. debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.8% |
| Accounts Receivable | €96.52K | 20.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DTC live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Defence Therapeutics Inc.'s current assets represent 44.8% of total assets in 2024, a decrease from 97.6% in 2020.
- Cash Position: Cash and equivalents constituted 11.8% of total assets in 2024, down from 97.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 20.2% of total assets.
Defence Therapeutics Inc. Competitors by Total Assets
Key competitors of Defence Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Defence Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.08 | 0.05 | 94.21 |
| Quick Ratio | 1.08 | 0.05 | 94.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €86.40K | €-3.66 Million | €7.05 Million |
Defence Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Defence Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 96.37 |
| Latest Market Cap to Assets Ratio | 36.03 |
| Asset Growth Rate (YoY) | -86.5% |
| Total Assets | €477.75K |
| Market Capitalization | $17.21 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Defence Therapeutics Inc.'s assets at a significant premium (36.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Defence Therapeutics Inc.'s assets decreased by 86.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual total assets of Defence Therapeutics Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €477.75K ≈ $558.54K |
-86.48% |
| 2023-06-30 | €3.53 Million ≈ $4.13 Million |
+390.88% |
| 2022-06-30 | €719.67K ≈ $841.37K |
-87.17% |
| 2021-06-30 | €5.61 Million ≈ $6.56 Million |
+193.38% |
| 2020-06-30 | €1.91 Million ≈ $2.24 Million |
-- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more